Cargando…

Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients

AIMS AND BACKGROUND: This study was designed to compare the efficacy and safety of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer (GC) patients. METHODS: Sixty patients were divided into TOF group and SOX groups randomly. Patients in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Xichao, Zhang, Xizhi, Wang, Chaomin, Jiang, Jingting, Wu, Changping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444759/ https://www.ncbi.nlm.nih.gov/pubmed/27911869 http://dx.doi.org/10.18632/oncotarget.13721

Ejemplares similares

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer
por: Cheeseman, S L, et al.
Publicado: (2002)

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
por: Lordick, F, et al.
Publicado: (2005)

Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen
por: Liu, Rujiao, et al.
Publicado: (2015)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
por: Comella, P, et al.
Publicado: (2002)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
por: Jeung, H-C, et al.
Publicado: (2006)

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil
por: Guglielmi, A, et al.
Publicado: (2004)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Association Between Polymorphism rs678653 in Human Cyclin D1 Gene (CCND1) and Susceptibility to Cancer: A Meta-Analysis
por: Dai, Xichao, et al.
Publicado: (2016)

Prognostic Significance of miR-181b and miR-21 in Gastric Cancer Patients Treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin
por: Jiang, Jingting, et al.
Publicado: (2011)

Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study
por: Chinen, Takashi, et al.
Publicado: (2022)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen
por: Goel, Gaurav
Publicado: (2012)

Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?
por: Azmy, A., et al.
Publicado: (2013)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer
por: Dreosti, Lydia M., et al.
Publicado: (2014)

The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2020)

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
por: Zhang, Fei, et al.
Publicado: (2019)

Adjuvant 5‐Fluorouracil/leucovorin, capecitabine, and oxaliplatin‐related regimens for stage II/III colon cancer patients 66 years or older
por: Jones, Emily, et al.
Publicado: (2022)

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens
por: Tavakoli Pirzaman, Ali, et al.
Publicado: (2023)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010)

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
por: Loi, S, et al.
Publicado: (2005)

Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
por: Teng, Chieh-Lin Jerry, et al.
Publicado: (2015)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
por: Nehls, O, et al.
Publicado: (2002)

Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
por: Neri, B, et al.
Publicado: (2007)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107
por: Teng, Rongyue, et al.
Publicado: (2015)

Fluorouracil/oxaliplatin: Coronary vasospasm and neutropenia: case report
Publicado: (2019)

Fluorouracil/oxaliplatin/panitumumab: Lack of efficacy: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fb0t1jqd3hdc3ahv0p0hs0ghk9